Assembly Biosciences (NASDAQ:ASMB) Stock Price Passes Above 200-Day Moving Average – What’s Next?

Assembly Biosciences, Inc. (NASDAQ:ASMB)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $28.32 and traded as high as $29.95. Assembly Biosciences shares last traded at $28.97, with a volume of 177,777 shares trading hands.

Analysts Set New Price Targets

ASMB has been the topic of a number of analyst reports. Mizuho set a $45.00 price objective on shares of Assembly Biosciences and gave the company an “outperform” rating in a research report on Monday, June 15th. Guggenheim reissued a “buy” rating and set a $43.00 price target on shares of Assembly Biosciences in a report on Thursday, May 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a report on Monday, May 4th. Finally, Wall Street Zen cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Assembly Biosciences has an average rating of “Moderate Buy” and an average price target of $44.00.

Assembly Biosciences Price Performance

The company’s 50 day moving average is $26.74 and its 200 day moving average is $28.24. The stock has a market cap of $442.85 million, a price-to-earnings ratio of -253.34 and a beta of 1.08.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.11. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. The company had revenue of $8.21 million for the quarter, compared to analyst estimates of $9.27 million. Sell-side analysts predict that Assembly Biosciences, Inc. will post 1.9 earnings per share for the current year.

Hedge Funds Weigh In On Assembly Biosciences

Hedge funds have recently bought and sold shares of the company. Informed Momentum Co LLC boosted its position in Assembly Biosciences by 1.6% during the fourth quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock worth $1,004,000 after purchasing an additional 451 shares in the last quarter. ADAR1 Capital Management LLC increased its position in shares of Assembly Biosciences by 4.2% in the fourth quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock valued at $672,000 after buying an additional 800 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Assembly Biosciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock valued at $4,468,000 after buying an additional 1,212 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Assembly Biosciences by 4.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock worth $1,095,000 after buying an additional 1,634 shares during the last quarter. Finally, Palumbo Wealth Management LLC boosted its position in shares of Assembly Biosciences by 7.2% in the 4th quarter. Palumbo Wealth Management LLC now owns 37,305 shares of the biopharmaceutical company’s stock worth $1,269,000 after buying an additional 2,507 shares in the last quarter. 19.92% of the stock is owned by hedge funds and other institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.